JP2018533954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533954A5 JP2018533954A5 JP2018524194A JP2018524194A JP2018533954A5 JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5 JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- expression
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194367 | 2015-11-12 | ||
| EP15194367.7 | 2015-11-12 | ||
| EP16189502.4 | 2016-09-19 | ||
| EP16189502 | 2016-09-19 | ||
| PCT/EP2016/077383 WO2017081223A1 (en) | 2015-11-12 | 2016-11-11 | Oligonucleotides for inducing paternal ube3a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136397A Division JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533954A JP2018533954A (ja) | 2018-11-22 |
| JP2018533954A5 true JP2018533954A5 (enExample) | 2020-04-09 |
| JP6751142B2 JP6751142B2 (ja) | 2020-09-02 |
Family
ID=57345910
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524194A Active JP6751142B2 (ja) | 2015-11-12 | 2016-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2018521433A Expired - Fee Related JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2018521433A Expired - Fee Related JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US10494633B2 (enExample) |
| EP (5) | EP4220360B9 (enExample) |
| JP (7) | JP6751142B2 (enExample) |
| KR (4) | KR102482440B1 (enExample) |
| CN (5) | CN108350431A (enExample) |
| AU (4) | AU2016352836B2 (enExample) |
| CA (1) | CA3004799C (enExample) |
| CL (3) | CL2018001189A1 (enExample) |
| CO (1) | CO2018004550A2 (enExample) |
| CR (3) | CR20200118A (enExample) |
| DK (2) | DK4220360T3 (enExample) |
| ES (2) | ES2991800T3 (enExample) |
| FI (1) | FI4220360T3 (enExample) |
| HK (2) | HK1258434A1 (enExample) |
| HR (2) | HRP20241138T1 (enExample) |
| HU (2) | HUE053197T2 (enExample) |
| IL (4) | IL325248A (enExample) |
| LT (2) | LT3374509T (enExample) |
| MA (1) | MA67580B1 (enExample) |
| MX (4) | MX2018004978A (enExample) |
| PE (2) | PE20210451A1 (enExample) |
| PH (1) | PH12018501005A1 (enExample) |
| PL (2) | PL4220360T3 (enExample) |
| RS (2) | RS66036B1 (enExample) |
| RU (1) | RU2742007C2 (enExample) |
| SG (1) | SG11201803951QA (enExample) |
| SI (2) | SI4220360T1 (enExample) |
| UA (1) | UA125963C2 (enExample) |
| WO (3) | WO2017081254A1 (enExample) |
| ZA (1) | ZA201802494B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| RU2562861C2 (ru) | 2009-09-11 | 2015-09-10 | Айсис Фармасьютикалс, Инк. | Модуляция экспрессии гентингтина |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| JP6294876B2 (ja) | 2012-06-25 | 2018-03-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｕｂｅ３ａ−ａｔｓ発現の調節 |
| CN112007045B (zh) | 2012-07-13 | 2026-01-06 | 波涛生命科学有限公司 | 手性控制 |
| DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| KR102423317B1 (ko) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
| US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| UA125963C2 (uk) | 2015-11-12 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Олігонуклеотид для індукції батьківської експресії ube3a |
| WO2019109001A1 (en) | 2017-12-01 | 2019-06-06 | The Texas A&M University System | Angelman syndrome antisense treatment |
| CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| EP3833398A4 (en) | 2018-09-21 | 2021-12-22 | University of Connecticut | COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS |
| US12360123B2 (en) | 2019-01-17 | 2025-07-15 | Hoffmann-La Roche Inc. | E3 ubiquitin ligase (UBE3A) protein targets |
| CA3130431A1 (en) * | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Phosphonoacetate gapmer oligonucleotides |
| CA3135180A1 (en) | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
| EA202193214A1 (ru) * | 2019-05-22 | 2022-03-14 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Гены ube3a и кассеты экспрессии и их использование |
| EP3976765A1 (en) | 2019-05-28 | 2022-04-06 | F. Hoffmann-La Roche AG | Method to generate monocytic progenitor cells |
| TW202204607A (zh) * | 2020-04-16 | 2022-02-01 | 英商羅斯林科技有限公司 | 誘導性多功能幹細胞(iPSC)之誘導 |
| US20230212572A1 (en) * | 2020-06-09 | 2023-07-06 | Roche Innovation Center Copenhagen A/S | Guanosine Analogues for Use in Therapeutics Polynucleotides |
| WO2022158487A1 (ja) | 2021-01-21 | 2022-07-28 | 藤森工業株式会社 | 積層フィルムおよび包装袋 |
| CN119173632A (zh) | 2022-05-10 | 2024-12-20 | 豪夫迈·罗氏有限公司 | 靶向cfp-elk1基因间区域的反义寡核苷酸 |
| WO2024227765A2 (en) | 2023-05-04 | 2024-11-07 | F. Hoffmann-La Roche Ag | Oligonucleotides capable of upregulating glucocerebrosidase expression |
| KR20250068540A (ko) * | 2023-11-08 | 2025-05-16 | 한국과학기술원 | Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도 |
| WO2025125542A1 (en) | 2023-12-15 | 2025-06-19 | F. Hoffmann-La Roche Ag | Intrathecal dosage method |
| WO2025213123A1 (en) * | 2024-04-05 | 2025-10-09 | Encoded Therapeutics, Inc. | Methods and compositions for increasing expression of ube3a |
| WO2025217466A1 (en) * | 2024-04-11 | 2025-10-16 | Ultragenyx Pharmaceutical Inc. | Dosing regimens for antisense treatment of angelman syndrome |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373084A (en) | 1981-07-07 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom |
| EP0724447B1 (en) | 1991-10-24 | 2003-05-07 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| PT1152009E (pt) | 1999-02-12 | 2005-03-31 | Sankyo Co | Novos analogos de nucleosidos e oligonucleotidos |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| EP1234174A1 (en) | 1999-12-02 | 2002-08-28 | Myriad Genetics, Inc. | Protein-protein interactions |
| US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
| WO2001092582A1 (en) * | 2000-06-01 | 2001-12-06 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
| US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
| AU2002315393A1 (en) * | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20050124572A1 (en) * | 2002-06-17 | 2005-06-09 | Freier Susan M. | Compositions and their uses directed to signal tranducers |
| WO2004016754A2 (en) | 2002-08-14 | 2004-02-26 | Pharmacia Corporation | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
| JP2006500066A (ja) * | 2002-09-25 | 2006-01-05 | ファルマシア・コーポレーション | ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節 |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| KR20060115351A (ko) | 2003-08-29 | 2006-11-08 | 위스콘신 얼럼나이 리서어치 화운데이션 | 영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런및 도파민 뉴런의 시험관내 분화 방법 |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| ES2351674T3 (es) | 2006-01-27 | 2011-02-09 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6. |
| DK2021472T3 (da) | 2006-05-05 | 2011-09-19 | Isis Pharmaceuticals Inc | Forbindelser og fremgangsmåder til modulering af genekspression |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| EP2176280B2 (en) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
| US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
| US8642334B2 (en) * | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| AU2010306377B2 (en) | 2009-10-13 | 2015-01-22 | Stemcell Technologies Canada Inc. | Manipulation of osmolality for differentiating stem cells |
| ES2661387T3 (es) | 2009-12-23 | 2018-03-28 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf |
| WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| NO2593547T3 (enExample) | 2010-07-14 | 2018-04-14 | ||
| EP3489360A3 (en) | 2010-07-19 | 2019-08-28 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
| KR101788903B1 (ko) * | 2010-08-19 | 2017-10-23 | 에프. 호프만-라 로슈 아게 | 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환 |
| WO2012064806A2 (en) | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
| WO2012068405A2 (en) | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
| JP2014514313A (ja) | 2011-04-20 | 2014-06-19 | ロシュ グリクアート アクチェンゲゼルシャフト | 血液脳関門のｐＨ依存性通過のための方法及び構築物 |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| SG11201401314PA (en) | 2011-09-07 | 2014-09-26 | Marina Biotech Inc | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| JP6294876B2 (ja) * | 2012-06-25 | 2018-03-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｕｂｅ３ａ−ａｔｓ発現の調節 |
| SG10201804331TA (en) | 2012-11-15 | 2018-07-30 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| DK3119881T3 (da) | 2014-03-21 | 2023-04-03 | Fujifilm Cellular Dynamics Inc | Production of midbrain dopaminergic neurons and methods for the use thereof |
| UA125963C2 (uk) * | 2015-11-12 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Олігонуклеотид для індукції батьківської експресії ube3a |
| RU2019143627A (ru) | 2017-06-28 | 2021-07-28 | Юниверсити Оф Соус Флорида | Модифицированный ген ube3a для генной терапии синдрома ангельмана |
| WO2019109001A1 (en) | 2017-12-01 | 2019-06-06 | The Texas A&M University System | Angelman syndrome antisense treatment |
| KR20200116088A (ko) | 2018-01-26 | 2020-10-08 | 에프. 호프만-라 로슈 아게 | 방사성 표지된 올리고뉴클레오티드 및 이의 제조 방법 |
| CA3135180A1 (en) | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
-
2016
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko active Active
- 2016-11-11 EP EP23152543.7A patent/EP4220360B9/en active Active
- 2016-11-11 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-11 IL IL325248A patent/IL325248A/en unknown
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 ES ES23152543T patent/ES2991800T3/es active Active
- 2016-11-11 SI SI201631843T patent/SI4220360T1/sl unknown
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en not_active Withdrawn
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 MA MA67580A patent/MA67580B1/fr unknown
- 2016-11-11 FI FIEP23152543.7T patent/FI4220360T3/fi active
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 RS RS20241003A patent/RS66036B1/sr unknown
- 2016-11-11 IL IL300119A patent/IL300119B2/en unknown
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-11 HR HRP20241138TT patent/HRP20241138T1/hr unknown
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 KR KR1020257024980A patent/KR20250121139A/ko active Pending
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en not_active Withdrawn
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en not_active Ceased
- 2016-11-11 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2016-11-11 PL PL23152543.7T patent/PL4220360T3/pl unknown
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 HU HUE23152543A patent/HUE067905T2/hu unknown
- 2016-11-11 DK DK23152543.7T patent/DK4220360T3/da active
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en not_active Ceased
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active Active
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja not_active Expired - Fee Related
- 2016-11-11 LT LTEP23152543.7T patent/LT4220360T/lt unknown
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en not_active Ceased
- 2016-11-11 KR KR1020227045154A patent/KR102840652B1/ko active Active
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
-
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en not_active Abandoned
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en not_active Abandoned
-
2019
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
-
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
-
2021
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
-
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
- 2022-08-05 AU AU2022211910A patent/AU2022211910B2/en active Active
-
2023
- 2023-01-25 AU AU2023200410A patent/AU2023200410B2/en active Active
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-02-22 US US18/172,707 patent/US12259380B2/en active Active
- 2023-10-20 US US18/491,513 patent/US12566172B2/en active Active
-
2024
- 2024-11-11 JP JP2024196762A patent/JP2025024060A/ja active Pending
-
2025
- 2025-07-02 US US19/258,035 patent/US12596118B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210227T1 (hr) | Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| WO2013074974A3 (en) | Modified rnai agents | |
| JP2018523668A5 (enExample) | ||
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| BR112013010525A2 (pt) | tratamento de hbv | |
| JP2017536366A5 (enExample) | ||
| JP2015516989A5 (enExample) | ||
| BR112015022876A2 (pt) | agente, composição farmacêutica e método para inibição da expressão do componente do complemento c5, uso do referido agente, vetor e célula. | |
| BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
| JP2018530530A5 (enExample) | ||
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| MX2025009778A (es) | Composicion farmaceutica de un oligonucleotido antisentido y su uso para el tratamiento del sindrome de angelman | |
| JP2021500016A5 (enExample) | ||
| JP2011515357A5 (enExample) | ||
| WO2013162350A3 (en) | Circular antiviral rna | |
| JP2011519365A5 (enExample) | ||
| IL274363B2 (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| RU2016141263A (ru) | Аптамер для fgf2 и его применение | |
| WO2015188198A3 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
| AR106543A1 (es) | Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético | |
| NZ741585B2 (en) | Oligonucleotides for inducing paternal ube3a expression | |
| TH1801002789A (th) | โอลิโกนิวคลีโอไทด์สำหรับการเหนี่ยวนำการแสดงออกของ ube3a จากทางพ่อ |